Candida albicans Infection

Description

BioModels offers a Candida albicans infection model. Candida albicans is the most commonly identified pathogenic Candida species in human infections and can impact both immunocompromised and healthy populations. C. albicans has adapted an expansive set of virulence factors and fitness attributes that enable this fungus to survive in extremely diverse environments and infect humans and animals through a variety of routes. This model could be used to assess candidate anti-fungal treatment efficacy or characterize the biodistribution of test articles in a model of systemic inflammation due to infection. Representative data shows infection kinetics including body weight, survival, and CFU in critical organs for multiple different routes of infection with C. albicans.

  • Advantages: natural human pathogen, optional localized or systemic infection, ability to alter disease severity based on route of infection.
  • Disadvantages: variability in fungal CFU recovery.
Model Systems
  • C57Bl/6 Mice
Standard Readouts
  • Survival
  • Percent weight change
  • Local and systemic fungal enumeration
Additional Readouts
  • Body temperature
  • Immunophenotyping
  • Terminal histopathology and/or IHC analyses
  • Cytokine analysis
  • Custom assays
Representative DataClick Image to Enlarge
Survival Rates in a Murine Model of Infection with C. albicans

Animals are observed daily for survival and morbidity. All infected groups are compared to naïve animals to assess for statistical significance.

Percent Weight Change in a Murine Model of Infection with C. albicans

Animals are weighed daily, and percent body weight change relative to Day 0 is calculated. AUCs are calculated to compare infected and uninfected animals and are shown in the figure inset (****p<0.0001).

Fungal Enumeration in Critically Infected Organs in a Murine Model of Infection with C. albicans (CFU/mL

Animals are euthanized 4 and 28 days post infection. Spleens, lungs, brains, kidneys, tongues, and livers are excised, processed, and plated for CFU enumeration.

Daniel Lichtman

Managing Partner